Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London

(TheNewswire)

Toronto, Ontario – TheNewswire- February 24, 2026 – Helix BioPharma Corp.(TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”)(“Helix” or the “Company”), a clinical-stage oncologycompany shaping a near future where today’s hard-to-treat cancersare vincible, is pleased to announce that the Company presented newdata yesterday on its CEACAM6-directed antibody-drug conjugate (ADC)program at the 16th Annual World ADC London conference, held inLondon, United Kingdom.

The presentation, titled “Next-Generation ADCs: Unlocking thePotential of CEACAM6-Directed Targeted Therapies”, was delivered by Jonathan Davis, PhD, Director of ADC Discoveryat Helix BioPharma, as part of the conference’s opening day. Dr.Davis was selected to present as part of the conference’s SeminarDay program, which brings together leading ADC experts to address keychallenges and opportunities in next-generation conjugate design,safety, combination strategies, and regulatory development. Hisparticipation underscores Helix’s growing leadership in thedevelopment of innovative ADC technologies. The World ADC Londonconference continues over the following two days with a comprehensivescientific program covering advances in ADC discovery, development,and clinical translation.  

The presentation highlighted CEACAM6 as a highlyattractive therapeutic target, based on its elevated expression acrossa broad range of epithelial cancers, its association with poorclinical outcomes, and its limited expression in healthy tissues. Dr.Davis also presented data supporting the tumor-selective bindingprofile of Helix’s proprietary anti-CEACAM6 VHH, a single-domainantibody fragment derived from camelid antibodies (also known as a“nanobody”), which demonstrated preferential binding totumor-expressed CEACAM6. This highly selective binding profilesupports the development of next-generation ADCs designed to deliverpotent therapeutic payloads directly to cancer cells while minimizingoff-target effects, and builds on the clinical foundation set by TumorDefense Breaker™, L-DOS47, Helix’s lead CEACAM6-targetedcandidate, which has demonstrated favorable safety and encouragingclinical activity in Phase I/II studies in non-small cell lung cancer(NSCLC).

“CEACAM6 represents a compelling and underexploitedtarget with broad potential across multiple hard-to-treat cancers,”said Dr. Davis. “Our proprietary VHH-based targeting approach enableshighly selective tumor binding, supporting the development ofnext-generation ADCs designed to maximize therapeutic impact whileminimizing off-target effects. Our presentation generated stronginterest and discussion among conference participants, reflecting thegrowing recognition of CEACAM6 as an important emerging target inoncology.”

A copy of Dr. Davis’ presentation is available on theCompany’s website under the “Events and Presentations” page at:https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.

About World ADC London

World ADC London is a global, annual conferencededicated to the discovery, development, and commercialization ofantibody-drug conjugates (ADCs). Now it its 16th year, it isthe longest-standing and one of the leading global conferencesdedicated to ADC research and development. The event brings togethermore than 700 industry stakeholders from over 240 companies, includingbiopharma organizations, clinicians, investors, and regulatoryexperts, as well as a global faculty of morethan 120 speakers. The conference provides a forum for scientificexchange, networking, and collaboration to advance next-generation ADCinnovation and targeted cancer therapies. Learn more at https://worldadc-europe.com/.

About Helix BioPharma

Helix BioPharma is an oncology company that innovatesfrom strength to bring near-term solutions for today’shardest-to-treat cancers. The Company’s pipeline is led by TumorDefense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugatedesigned to prime CEACAM6-expressing tumors for increased sensitivityto therapy and augment the effectiveness of today’s front-runninganti-cancer treatments. L-DOS47 has completed Phase Ib studies innon-small cell lung cancer (NSCLC) and shares its CEACAM6-targetingfoundation with Helix’s next-generation bi-specific antibody-drugconjugates (ADCs), currently in discovery. The Company also advancestwo pre-IND candidates: (i) LEUMUNA™, an oral immune checkpointmodulator aimed at achieving durable remission in post-transplantleukemia relapse, and (ii) GEMCEDA™, a first-in-class oralgemcitabine prodrug with bioavailability on a par with IV, designed toexpand treatment options for advanced cancers.

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB(HBP0). For more information, pleasevisit: https://www.helixbiopharma.com/

For more information, pleasecontact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2700

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Jacek Antas, Director

corporate@helixbiopharma.com

Forward-Looking Statements and Risksand Uncertainties

This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to DOS47, LEUMUNA™ andGEMCEDA™. Forward-looking statements can further be identified bythe use of forward-looking terminology such as “ongoing”,“estimates”, “expects”, or the negative thereof or any othervariations thereon or comparable terminology referring to futureevents or results, or that events or conditions “will”, “may”,“could”, or “should” occur or be achieved, or comparableterminology referring to future events or results.

Forward-looking statements arenecessarily based on a number of estimates and assumptions that theCompany considered appropriate and reasonable as of the date suchinformation is given, including but not limited to the assumptionsregarding the implied benefits of the transactions. Forward-lookingstatements are subject to known and unknown risks, uncertainties, andother factors, many of which are beyond the Company’s control, thatmay cause actual results, performance or achievements to be materiallydifferent from those expressed or implied by such forward-lookingstatements, including but not limited to the risk that theCompany's assumptions on which its forward-looking statements arebased may not be accurate; the ability of the Company to capitalize onthe potential benefits of the transactions; and the risk factorsdisclosed in the Company's periodic reports publicly filed andavailable on its SEDAR+ profile at www.sedarplus.ca. No assurance can be given that any ofthe events anticipated by the forward-looking statements willtranspire or occur. There is no assurance that the proposedtransactions will be completed in accordance with its terms or at all.The forward-looking statements contained in this news release are madeas of the date of this announcement and the Company does not assumeany obligation to update any forward-looking statement or informationshould those beliefs, assumptions, opinions or expectations, or othercircumstances change, except as required by law.

Copyright (c) 2026 TheNewswire - All rights reserved.